A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication

Part of paid clinical trials in Glendale, California.

Sponsor
Novo Nordisk A/S
Study ID
NCT07855133
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Semaglutide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.
  • Zenagamtide — DRUG
    Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Study Details

The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get semaglutide and zenagamtide.

Key Dates

First listed
Oct 2, 2026
Start date
Sep 30, 2026
Status verified
Sep 2026
Primary completion
Sep 6, 2028
Completion
Sep 6, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide and Zenagamtide
    Participants will receive one of the different dose levels of semaglutide administered once weekly by subcutaneous injection. Following the last maintenance dose of semaglutide, participants will switch to one of the different dose levels of zenagamtide administered once weekly by subcutaneous injection.

Primary Outcome Measure

Number of treatment emergent adverse events (TEAE) [ Time Frame: From first administration of zenagamtide day 1 to day 57 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
PAREXEL Glendale/LA EPCUGlendaleCalifornia91206-
PAREXEL Intl - EPCU-BaltimoreBaltimoreMaryland21225-

Find similar trials in Glendale, CA

Nationwide
Obesity / overweight trialsType 2 diabetes trialsEndocrinology trialsMetabolic health trialsWeight loss trials
By condition
Obesity / overweightType 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
PAREXEL Glendale/LA EPCU· Glendale, CAPAREXEL Intl - EPCU-Baltimore· Baltimore, MD

Related Studies